Page 2 - Dr Reddy’s Laboratories

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Dr Reddy's Q4 results: Net profit rises 36% to Rs 1,307 cr, revenue up 12%

Q4FY24 results: The company board has recommended a final dividend of Rs 40 per equity share of Rs 5 each for the financial year 2023-24

Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results

Indian pharmaceutical giant Dr Reddy's Laboratories is set to witness a single to double digit growth in sales on a year-on-year (Y-o-Y) basis for the fourth quarter of financial year 2023-24 (Q4FY23)

Nestle India Q4FY24 results: Net profit soars 27% to Rs 934 crore

Company to launch Nespresso in India, announces joint venture with Dr. Reddy's Laboratories

Dr Reddy's to market Bayer's second brand of heart failure drug in India

Under the agreement, Dr Reddy's will market Vericiguat under the brand name Gantra

Market resilience in a pill: Pharma's formula for Q3 earnings upgrades

Rx for returns: Pharma firms' dominance in market recovery prescription

Dr Reddy's rallies 4%; market cap touches Rs 1 trillion post Q3 results

With this, Dr Reddy's has become the third listed pharmaceutical company to achieve the Rs 1-trillion m-cap feat

Dr Reddy's launches wearable device for drug-free management of migraine

In January this year, Dr Reddy's entered an exclusive agreement with Theranica for the marketing and distribution of Nerivio in India

Dr Reddy's Laboratories Q1 PAT up 18% to Rs 1,402 cr on India, Russia biz

With cash surplus of Rs 4980 crore, pharma major looking at inorganic opportunities

Dr Reddy's Labs Q1FY24 results: Net profit up 18% YoY to Rs 1,402.5 cr

As compared to Rs 959.2 crore in the quarter that ended on March 31, the net profit was up 46%

Dr Reddy's application for biosimilar candidate accepted for USFDA's review

Dr Reddy's Laboratories on Wednesday said its biologics licence application for its proposed biosimilar rituximab candidate has been accepted for a substantive review by the US Food and Drug Administration (USFDA). This closely follows acceptance of the rituximab biosimilar dossier for review by two other regulatory agencies -- the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Rituximab is used to treat certain autoimmune diseases and types of cancer. "This milestone underscores our capability for global clinical development of high-quality biosimilar products for highly regulated and global markets," Dr Reddy's Global Head of Biologics Jayanth Sridhar said in a statement. It also reinforces the potential of the product as a safe and effective treatment option for patients across the globe, he added. Development and commercialisation of biological drugs is an important growth lever for the company's business, Sridhar ...

Dr Reddy's Laboratories forays into new terrain to give 'top-5' aim a shot

Analysts think that these new entries may help the company navigate multiple risks in the Indian branded market

Dr Reddy's completes Phase-I study in proposed biosimilar of tocilizumab

Global Phase III study is being initiated to compare the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product

Dr Reddy's Laboratories QoQ showing catches a cold on weak US sales

While pharma major has maintained its margin guidance, expensive valuations limit upside

Dr Reddy's Laboratories Q4 PAT grows nine-fold riding on US, India biz

For the full year 2022-23, DRL's revenues were up 15 percent to Rs 24,587.9 crore while the PAT grew by 91 percent to Rs 4,506.7 crore

Dr Reddy's acquires Mayne Pharma's USA prescription portfolio for $105 mn

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia

Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters

Sensex slumps 774 pts, Nifty ends below 17900; Auto, FMCG stocks outshine

Stock market LIVE: As per rollover data, the Nifty index has, so far, witnessed rollover in-line with the last three months' averages. However, slight declines in roll cost indicates a capped upside

Stocks to Watch: Wipro, HDFC Bank, DMart, Delhivery, NDTV, Sula Vineyard

Stocks to Watch today: Wipro, after market hours on Friday, reported a consolidated net profit of Rs 3,052 crore for October-December FY23, an increase of 2.8 per cent year-on-year (YoY)

Dr Reddy's acquires trademark rights for Pfizer breast cancer drug

Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv